Drug intelligence / Profile preview

NPL-101

Development stage: Preclinical
Lead developer: Novatek Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NPL-101 is a biosimilar monoclonal antibody candidate developed by Novatek Pharmaceuticals. It is designed to target the programmed cell death protein 1 (PD-1) immune checkpoint, a key regulator of T-cell activity. By binding to PD-1, NPL-101 blocks its interaction with ligands PD-L1 and PD-L2, which are often exploited by tumor cells to evade immune detection. This blockade releases the inhibition of T-cell activation, thereby enhancing the body's anti-tumor immune response. NPL-101 is being developed for multiple oncology indications as part of Novatek's immunotherapy pipeline.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on NPL-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPL-101.

Explore the full profile